A Phase 2 interventional study of CSL324 and Placebo in Coronavirus Disease 2019 (COVID-19), sponsored by CSL Behring. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 2, prospective, multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the safety and efficacy of intravenous (IV) administration of CSL324, administered in combination with SOC treatment, in subjects with COVID 19.
For the purposes of this study, standard of care (SOC) may include any written or established treatment protocol followed at the study site for the treatment of severe COVID-19 or its complications, including off-label use of marketed pharmaceutical products and / or products with emergency use authorization granted for the treatment of COVID-19 (ie, not yet marketed) (eg, remdesivir).
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
First submitted after CSL Behring became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets ≥ 1 of the following criteria (subjects improving while on respiratory support still qualify):
Exclusion Criteria:
Currently enrolled, planning to enroll, or participated, within the last 30 days, in a clinical study requiring administration of an product (ie, not yet marketed), including expanded access or compassionate use
Exceptions:
Intubated and requires mechanical ventilation (including ECMO) at time of randomization
Presence of any of the following comorbid conditions before randomization and prior to SARS-CoV-2 infection:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CSL324 administered intravenously
Biological: CSL324
Normal saline administered intravenously
Drug: Placebo
Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Normal saline (0.9% sodium chloride)
Proportion of subjects progressing to endotracheal intubation or death prior to endotracheal intubation
Time frame: Randomization to Day 28
Proportion of deaths from all causes
Time frame: Randomization to Day 28
Proportion of subjects intubated
Time frame: Randomization to Day 28
Median length of stay in hospital
Time frame: Randomization to Day 28
Number and proportion of subjects with at least a 2-point improvement in the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale
Time frame: Randomization to Day 28
Number and proportion of subjects within each of the categories of the NIAID ordinal scale
Time frame: Daily up to Day 28
Proportion of subjects using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP)
Time frame: Randomization to Day 28
Proportion of subjects using high-flow nasal cannula (HFNC)
Time frame: Randomization to Day 28
Proportion of subjects using extracorporeal membrane oxygenation (ECMO)
Time frame: Randomization to Day 28
Maximum Change in Sequential Organ Failure Assessment (SOFA) score
Time frame: Randomization to Day 28
Change in SOFA score and in individual components of the SOFA score
Time frame: Baseline to Day 28
Number and proportion of subjects experiencing adverse events (AEs)
Time frame: Up to 60 days
Number and proportion of subjects experiencing serious adverse events (SAEs)
Time frame: Up to 60 days
Number and proportion of subjects experiencing adverse events of special interest (AESIs)
Time frame: Up to 60 days
Presence of anti-CSL324 antibodies
Time frame: Up to 28 days
Maximum concentration (Cmax) of CSL324
Time frame: Up to 28 days
Time to reach maximum concentration (Tmax) of CSL324
Time frame: Up to 28 days
Area under the concentration-time curve (AUC0-last) of CSL324
Time frame: Up to 28 days
Trough concentration (Ctrough) of CSL324
Time frame: Before dose on Day 4 and Day 8
No study locations are listed for this record.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
No publications or documents are linked to this record.
Start is estimated for Sep 2020; primary completion for Apr 2021, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anumigilimab